Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rallybio Corporaton (NQ: RLYB )

1.030 +0.040 (+4.04%)
Streaming Delayed Price Updated: 2:17 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rallybio Corporaton

< Previous 1 2 3 4 5 6 Next >
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
From Rallybio Corporation
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
Where Rallybio Stands With Analysts
Via Benzinga
Analyst Ratings for Rallybio
Via Benzinga
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
From Rallybio Corporation
Via Business Wire
Rallybio to Present at Upcoming Investor Conferences in September
From Rallybio Corporation
Via Business Wire
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
From Rallybio Corporation
Via Business Wire
Analyst Ratings for Rallybio
Via Benzinga
The Latest Analyst Ratings for Rallybio
Via Benzinga
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
From Rallybio Corporation
Via Business Wire
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
From Rallybio Corporation
Via Business Wire
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for... 
Via Benzinga
Rallybio to Present at the Jefferies Healthcare Conference
From Rallybio Corporation
Via Business Wire
Rallybio Reports First Quarter 2023 Financial Results
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
From Rallybio Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 17, 2023
Via Benzinga
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)
From Rallybio Corporation
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers for Thursday with all the companies traders need to watch! 
Via InvestorPlace
Rallybio Pulls Plug On One Candidate After Highlighting Encouraging Data From Another Thrombocytopenia Program
Via Benzinga
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
From Rallybio Corporation
Via Business Wire
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
EyePoint Pharma Posts Deeper Losses For Q4, Expects Cash Runway Into 2024
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported Q4 revenues of $10.5 million, down 8.8% Y/Y, almost in line with the consensus of $10.40 million. 
Via Benzinga
Rallybio to Present at Upcoming Investor Conferences in March
From Rallybio Corporation
Via Business Wire
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
From Rallybio Corporation
Via Business Wire
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.